PEOPLE ON THE MOVE
Atopix Therapeutics
Atopix Therapeutics, a UK drug company developing medicines for atopic dermatitis and severe asthma, has appointed Andrew Zambanini as chief medical officer.
Zambanini is a clinical pharmacologist and doctor with experience in pharmacovigilance and clinical development. His previous companies include GSK, where he was vice president, Takeda, Novartis, Kyowa Hakko Kirin UK, ProStrakan, Gilead, and Circassia.
Atopix is currently running clinical trials for its CRTH2 antagonist, OC459, in several indications in Th2-mediated disease.